# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $75 to $77.
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $85 to ...
RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $76...
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Hold and raises the price target from...